Genetic variation in SIPA1 in relation to breast cancer risk and survival after breast cancer diagnosis

Mia M. Gaudet, Kent Hunter, Paul Pharoah, Alison M. Dunning, Kristy Driver, Jolanta Lissowska, Mark Sherman, Beata Peplonska, Louise A. Brinton, Stephen Chanock, Montserrat Garcia-Closas

Research output: Contribution to journalArticle

Abstract

Genetic variation in SIPA1, signal-induced proliferation-associated gene 1, has been proposed to be associated with aggressive breast tumor characteristics related to metastasis and worse prognosis in humans and rodents. To test this hypothesis, we genotyped 3 single nucleotide polymorphisms (SNP) located at -3092 (AT, rs3741378), and exon 14 1 14 (C>T, rs746429), and examined them in relation to breast cancer risk and overall survival, stratified by tumor characteristics in 2 independent case-control studies conducted in Poland (1,995 cases, 2,296 controls) and in Britain (2,142 cases, 2,257 controls). Vital status (n = 396 deaths) was available for 911 Polish and 1,919 British breast cancer cases with an average follow-up time of 5.5 years. Overall, we found no significant associations between genetic variants of SIPA1 SNPs and breast cancer risk (per allele odds ratios, 95% confidence intervals (CI): rs931127-0.99, 0.931.06; rs3741378-1.03, 0.94-1.13; and, rs74642-0.98, 0.92-1.04). In both studies, SIPA1 polymorphisms were not related to overall mortality (per allele hazard ratios, 95% CI: 1.02, 0.88-1.17; 0.90, 0.72-1.11; 1.04, 0.90-1.21, respectively). Our results do not support a relationship between SIPA1 polymorphisms and breast cancer risk or subsequent survival.

Original languageEnglish (US)
Pages (from-to)1716-1720
Number of pages5
JournalInternational Journal of Cancer
Volume124
Issue number7
DOIs
StatePublished - Apr 1 2009
Externally publishedYes

Fingerprint

Breast Neoplasms
Survival
Single Nucleotide Polymorphism
Alleles
Confidence Intervals
Poland
Case-Control Studies
Exons
Rodentia
Odds Ratio
Neoplasm Metastasis
Mortality
Genes
Neoplasms

ASJC Scopus subject areas

  • Cancer Research
  • Oncology
  • Medicine(all)

Cite this

Gaudet, M. M., Hunter, K., Pharoah, P., Dunning, A. M., Driver, K., Lissowska, J., ... Garcia-Closas, M. (2009). Genetic variation in SIPA1 in relation to breast cancer risk and survival after breast cancer diagnosis. International Journal of Cancer, 124(7), 1716-1720. https://doi.org/10.1002/ijc.23919

Genetic variation in SIPA1 in relation to breast cancer risk and survival after breast cancer diagnosis. / Gaudet, Mia M.; Hunter, Kent; Pharoah, Paul; Dunning, Alison M.; Driver, Kristy; Lissowska, Jolanta; Sherman, Mark; Peplonska, Beata; Brinton, Louise A.; Chanock, Stephen; Garcia-Closas, Montserrat.

In: International Journal of Cancer, Vol. 124, No. 7, 01.04.2009, p. 1716-1720.

Research output: Contribution to journalArticle

Gaudet, MM, Hunter, K, Pharoah, P, Dunning, AM, Driver, K, Lissowska, J, Sherman, M, Peplonska, B, Brinton, LA, Chanock, S & Garcia-Closas, M 2009, 'Genetic variation in SIPA1 in relation to breast cancer risk and survival after breast cancer diagnosis', International Journal of Cancer, vol. 124, no. 7, pp. 1716-1720. https://doi.org/10.1002/ijc.23919
Gaudet, Mia M. ; Hunter, Kent ; Pharoah, Paul ; Dunning, Alison M. ; Driver, Kristy ; Lissowska, Jolanta ; Sherman, Mark ; Peplonska, Beata ; Brinton, Louise A. ; Chanock, Stephen ; Garcia-Closas, Montserrat. / Genetic variation in SIPA1 in relation to breast cancer risk and survival after breast cancer diagnosis. In: International Journal of Cancer. 2009 ; Vol. 124, No. 7. pp. 1716-1720.
@article{49488ab1798045ecb192817d2e287bde,
title = "Genetic variation in SIPA1 in relation to breast cancer risk and survival after breast cancer diagnosis",
abstract = "Genetic variation in SIPA1, signal-induced proliferation-associated gene 1, has been proposed to be associated with aggressive breast tumor characteristics related to metastasis and worse prognosis in humans and rodents. To test this hypothesis, we genotyped 3 single nucleotide polymorphisms (SNP) located at -3092 (AT, rs3741378), and exon 14 1 14 (C>T, rs746429), and examined them in relation to breast cancer risk and overall survival, stratified by tumor characteristics in 2 independent case-control studies conducted in Poland (1,995 cases, 2,296 controls) and in Britain (2,142 cases, 2,257 controls). Vital status (n = 396 deaths) was available for 911 Polish and 1,919 British breast cancer cases with an average follow-up time of 5.5 years. Overall, we found no significant associations between genetic variants of SIPA1 SNPs and breast cancer risk (per allele odds ratios, 95{\%} confidence intervals (CI): rs931127-0.99, 0.931.06; rs3741378-1.03, 0.94-1.13; and, rs74642-0.98, 0.92-1.04). In both studies, SIPA1 polymorphisms were not related to overall mortality (per allele hazard ratios, 95{\%} CI: 1.02, 0.88-1.17; 0.90, 0.72-1.11; 1.04, 0.90-1.21, respectively). Our results do not support a relationship between SIPA1 polymorphisms and breast cancer risk or subsequent survival.",
author = "Gaudet, {Mia M.} and Kent Hunter and Paul Pharoah and Dunning, {Alison M.} and Kristy Driver and Jolanta Lissowska and Mark Sherman and Beata Peplonska and Brinton, {Louise A.} and Stephen Chanock and Montserrat Garcia-Closas",
year = "2009",
month = "4",
day = "1",
doi = "10.1002/ijc.23919",
language = "English (US)",
volume = "124",
pages = "1716--1720",
journal = "International Journal of Cancer",
issn = "0020-7136",
publisher = "Wiley-Liss Inc.",
number = "7",

}

TY - JOUR

T1 - Genetic variation in SIPA1 in relation to breast cancer risk and survival after breast cancer diagnosis

AU - Gaudet, Mia M.

AU - Hunter, Kent

AU - Pharoah, Paul

AU - Dunning, Alison M.

AU - Driver, Kristy

AU - Lissowska, Jolanta

AU - Sherman, Mark

AU - Peplonska, Beata

AU - Brinton, Louise A.

AU - Chanock, Stephen

AU - Garcia-Closas, Montserrat

PY - 2009/4/1

Y1 - 2009/4/1

N2 - Genetic variation in SIPA1, signal-induced proliferation-associated gene 1, has been proposed to be associated with aggressive breast tumor characteristics related to metastasis and worse prognosis in humans and rodents. To test this hypothesis, we genotyped 3 single nucleotide polymorphisms (SNP) located at -3092 (AT, rs3741378), and exon 14 1 14 (C>T, rs746429), and examined them in relation to breast cancer risk and overall survival, stratified by tumor characteristics in 2 independent case-control studies conducted in Poland (1,995 cases, 2,296 controls) and in Britain (2,142 cases, 2,257 controls). Vital status (n = 396 deaths) was available for 911 Polish and 1,919 British breast cancer cases with an average follow-up time of 5.5 years. Overall, we found no significant associations between genetic variants of SIPA1 SNPs and breast cancer risk (per allele odds ratios, 95% confidence intervals (CI): rs931127-0.99, 0.931.06; rs3741378-1.03, 0.94-1.13; and, rs74642-0.98, 0.92-1.04). In both studies, SIPA1 polymorphisms were not related to overall mortality (per allele hazard ratios, 95% CI: 1.02, 0.88-1.17; 0.90, 0.72-1.11; 1.04, 0.90-1.21, respectively). Our results do not support a relationship between SIPA1 polymorphisms and breast cancer risk or subsequent survival.

AB - Genetic variation in SIPA1, signal-induced proliferation-associated gene 1, has been proposed to be associated with aggressive breast tumor characteristics related to metastasis and worse prognosis in humans and rodents. To test this hypothesis, we genotyped 3 single nucleotide polymorphisms (SNP) located at -3092 (AT, rs3741378), and exon 14 1 14 (C>T, rs746429), and examined them in relation to breast cancer risk and overall survival, stratified by tumor characteristics in 2 independent case-control studies conducted in Poland (1,995 cases, 2,296 controls) and in Britain (2,142 cases, 2,257 controls). Vital status (n = 396 deaths) was available for 911 Polish and 1,919 British breast cancer cases with an average follow-up time of 5.5 years. Overall, we found no significant associations between genetic variants of SIPA1 SNPs and breast cancer risk (per allele odds ratios, 95% confidence intervals (CI): rs931127-0.99, 0.931.06; rs3741378-1.03, 0.94-1.13; and, rs74642-0.98, 0.92-1.04). In both studies, SIPA1 polymorphisms were not related to overall mortality (per allele hazard ratios, 95% CI: 1.02, 0.88-1.17; 0.90, 0.72-1.11; 1.04, 0.90-1.21, respectively). Our results do not support a relationship between SIPA1 polymorphisms and breast cancer risk or subsequent survival.

UR - http://www.scopus.com/inward/record.url?scp=61449175948&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=61449175948&partnerID=8YFLogxK

U2 - 10.1002/ijc.23919

DO - 10.1002/ijc.23919

M3 - Article

VL - 124

SP - 1716

EP - 1720

JO - International Journal of Cancer

JF - International Journal of Cancer

SN - 0020-7136

IS - 7

ER -